XML 33 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1

Revenues (Tables)

6 Months Ended

Jun. 30, 2018

Revenue from Contract with Customer [Abstract]

Disaggregation of revenue by product and by geographic area

Revenues were as follows (in millions):

		Three months ended June 30,
		2018												2017
		US				ROW				Total				US				ROW				Total
Enbrel®		1,252				50				1,302				1,411				55				1,466
Neulasta®		948				152				1,100				937				150				1,087
Prolia®		396				214				610				326				179				505
Aranesp®		241				231				472				288				247				535
Sensipar® / Mimpara®		330				90				420				342				85				427
XGEVA®		339				113				452				292				103				395
EPOGEN®		250				—				250				292				—				292
Other products		611				462				1,073				498				369				867
Total product sales(1)		$	4,367			$	1,312			$	5,679			$	4,386			$	1,188			$	5,574
Other revenues										380												236
Total revenues(2)										$	6,059											$	5,810

		Six months ended June 30,
		2018												2017
		US				ROW				Total				US				ROW				Total
Enbrel®		2,302				105				2,407				2,529				118				2,647
Neulasta®		1,957				298				2,255				1,985				312				2,297
Prolia®		716				388				1,104				605				325				930
Aranesp®		466				460				926				566				480				1,046
Sensipar® / Mimpara®		739				178				917				679				169				848
XGEVA®		671				226				897				590				207				797
EPOGEN®		494				—				494				562				—				562
Other products		1,169				853				2,022				965				681				1,646
Total product sales(1)		$	8,514			$	2,508			$	11,022			$	8,481			$	2,292			$	10,773
Other revenues										591												501
Total revenues(2)										$	11,613											$	11,274

^____________ 

⁽¹⁾  Total product sales includes $20 million related to hedging losses and $33 million related to hedging gains for the three months ended June 30, 2018 and 2017, respectively. Total product sales includes $54 million related to hedging losses and $90 million related to hedging gains for the six months ended June 30, 2018 and 2017, respectively.

⁽²⁾  Prior-period amounts are not adjusted under the modified-retrospective method of adoption.

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration